SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-21-012936
Filing Date
2021-06-25
Accepted
2021-06-25 16:12:24
Documents
13
Period of Report
2021-06-25
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K auph-20210625.htm   iXBRL 8-K 43177
2 EX-99.1 exhibit991june252021.htm EX-99.1 25209
  Complete submission text file 0001628280-21-012936.txt   212892

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT auph-20210625.xsd EX-101.SCH 1942
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT auph-20210625_lab.xml EX-101.LAB 23970
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT auph-20210625_pre.xml EX-101.PRE 12668
6 EXTRACTED XBRL INSTANCE DOCUMENT auph-20210625_htm.xml XML 10774
Mailing Address #1203-4464 MARKHAM STREET VICTORIA BC A1 V8Z 7X8
Business Address #1203-4464 MARKHAM STREET VICTORIA BC A1 V8Z 7X8 250-708-4272
Aurinia Pharmaceuticals Inc. (Filer) CIK: 0001600620 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36421 | Film No.: 211047831
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences